301033SZSE
🚨 Material Event

Summary of Guangzhou Medprin Regenerative Medicine Technology Co., Ltd. Issuing Shares and Paying Cash to Purchase Assets and Raise Supporting Funds, and Related Party Transaction Report (Draft)

Maple Medical Co., Ltd.··66 pages

✨ AI Summary

Guangzhou Medprin Regenerative Medicine Technology Co., Ltd. proposes to issue shares and pay cash to acquire 100% of the equity in Guangzhou Med-Tech Medical Technology Co., Ltd. The transaction is valued at RMB 334.8494 million. The company also plans to raise supporting funds of RMB 133.5764 million. This transaction is classified as a major asset restructuring.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Statement

The words or abbreviations in this section have the same meaning as those in the "Definitions" section of this report.

I. Listed Company Statement

The Company and its directors, supervisors, and senior management guarantee that the information disclosed by the listed company is timely, fair, and accurate, complete, and does not contain any false or misleading statements or material omissions. They also guarantee the truthfulness and reasonableness of the relevant data cited in this report and bear corresponding legal responsibility for the truthfulness, accuracy, and completeness of the information provided.

If the information disclosed or provided in this transaction is suspected of containing false or misleading statements or material omissions, and is under investigation by judicial authorities or the China Securities Regulatory Commission (CSRC), the relevant shares will not be transferred until an investigation conclusion is formed. Within two trading days of receiving the investigation notice, a written application to suspend trading and the stock account will be submitted to the board of directors of the listed company, which will then apply for a lock-up with the stock exchange and securities registration and settlement institution on behalf of the shareholder. If the lock-up application is not submitted within two trading days, the board of directors is authorized to verify the information and directly report the identity and account information of the shareholder to the stock exchange and securities registration and settlement institution to apply for a lock-up. If the board of directors fails to report the identity and account information of the shareholder to the stock exchange and securities registration and settlement institution, the stock exchange and securities registration and settlement institution are authorized to directly lock up the relevant shares. If the investigation concludes that there are illegal or irregular activities, the shareholder agrees to voluntarily use the locked-up shares for compensation arrangements for relevant investors.

The China Securities Regulatory Commission and the Shenzhen Stock Exchange's decisions or opinions on this transaction do not represent their substantive judgment or guarantee of the company's stock value or investor returns.

In accordance with the "Securities Law" and other relevant laws and regulations, after the completion of this transaction, the company will be responsible for changes in its operations and profits, and investors will be responsible for the investment risks arising from these changes. When evaluating this transaction, investors should carefully consider the risk factors disclosed in this report, in addition to the content of this report and other relevant documents disclosed simultaneously. If investors have any questions about this report, they should consult their stockbroker, lawyer, accountant, or other professional advisor.

II. Statement of the Transaction Counterparty

The transaction counterparties for this restructuring have issued letters of commitment regarding the truthfulness, accuracy, and completeness of the information and materials provided during this transaction, guaranteeing that they will provide relevant information for this restructuring in a timely manner and that all information provided for this transaction is true, accurate, and complete. If the information provided contains false or misleading statements or material omissions, causing losses to the listed company or investors, they will be liable for compensation according to law.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.